Unlike earlier weight-loss medications, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Here's what to do: Powder Won't Dissolve Completely Some lyophilized peptides are stubborn, especially if the vial has been stored at low temperatures and the powder is densely compacted
This study provides insight into the molecular-level mechanism of physiological substrate recognition by SVMPs
Regulatory Status in Canada Retatrutide is not yet approved by Health Canada
Long-term gastrointestinal outcomes of COVID-19
According to the American Diabetes Association Standards of Care, cardiovascular disease remains the leading cause of morbidity and mortality in individuals with diabetes